The iconic rise of copyright’s flagship product presented a significant prospect for shareholders , but its patent has lapsed , creating a complex landscape. Off-brand versions have entered the market , cutting into revenues and putting a squeeze on profit margins . While leading drug companies continue a foothold in this sector , the outlook see